BACKGROUND: China's National Free Antiretroviral Treatment program has scaled-up rapidly since 2002, leading to a significant reduction of mortality among its participants. However, few studies have evaluated indicators for patient access to medical care and their association with mortality. METHODS: Patients enrolled into this national program between June 2002 and June 2009 for at least 7.5 months were retrospectively analyzed. RESULTS: Twenty-seven thousand five hundred four patients were included into the analysis, among whom 10,034 (37%) had at least 1 missed visit during the first 6 months of treatment. In Cox proportional hazard regression analysis, controlled for baseline demographic and clinical factors, patients with more missed visits had a higher risk of mortality, with an adjusted hazard ratio of 1.3 (95% confidence interval: 1.1 to 1.5) for 1-2 missed visits and 1.7 (95% confidence interval 1.4 to 2.2) for ≥3 missed visits compared with patients with no missed visits. In multivariate logistic regression models, factors independently associated with a higher likelihood of early missed visits included female gender, age >60, HIV transmission via injection drug use or via plasma donation compared with sexual transmission, baseline alanine aminotransferase >100 IU/L, having more symptoms at antiretroviral therapy initiation and receiving a didanosine-based regimen compared with lamivudine-based regimen. Lower baseline CD4 count was protective against missed visits. CONCLUSIONS: Missing early visits occurred in a sizable number of patients in this cohort and was associated with a higher mortality rate. Early missed visits may serve as an early warning indicator to trigger additional outreach effort.
BACKGROUND: China's National Free Antiretroviral Treatment program has scaled-up rapidly since 2002, leading to a significant reduction of mortality among its participants. However, few studies have evaluated indicators for patient access to medical care and their association with mortality. METHODS:Patients enrolled into this national program between June 2002 and June 2009 for at least 7.5 months were retrospectively analyzed. RESULTS: Twenty-seven thousand five hundred four patients were included into the analysis, among whom 10,034 (37%) had at least 1 missed visit during the first 6 months of treatment. In Cox proportional hazard regression analysis, controlled for baseline demographic and clinical factors, patients with more missed visits had a higher risk of mortality, with an adjusted hazard ratio of 1.3 (95% confidence interval: 1.1 to 1.5) for 1-2 missed visits and 1.7 (95% confidence interval 1.4 to 2.2) for ≥3 missed visits compared with patients with no missed visits. In multivariate logistic regression models, factors independently associated with a higher likelihood of early missed visits included female gender, age >60, HIV transmission via injection drug use or via plasma donation compared with sexual transmission, baseline alanine aminotransferase >100 IU/L, having more symptoms at antiretroviral therapy initiation and receiving a didanosine-based regimen compared with lamivudine-based regimen. Lower baseline CD4 count was protective against missed visits. CONCLUSIONS: Missing early visits occurred in a sizable number of patients in this cohort and was associated with a higher mortality rate. Early missed visits may serve as an early warning indicator to trigger additional outreach effort.
Authors: Awachana Jiamsakul; Stephen J Kerr; Sasisopin Kiertiburanakul; Iskandar Azwa; Fujie Zhang; Romanee Chaiwarith; Wingwai Wong; Penh Sun Ly; Nagalingeswaran Kumarasamy; Rossana Ditangco; Sanjay Pujari; Evy Yunihastuti; Cuong Duy Do; Tuti Parwati Merati; Kinh Van Nguyen; Man Po Lee; Jun Yong Choi; Shinichi Oka; Pacharee Kantipong; Benedict L H Sim; Oon Tek Ng; Jeremy Ross; Matthew Law Journal: AIDS Care Date: 2018-07-18
Authors: Jessica S Merlin; Andrew O Westfall; James L Raper; Anne Zinski; Wynne E Norton; James H Willig; Robert Gross; Christine S Ritchie; Michael S Saag; Michael J Mugavero Journal: J Acquir Immune Defic Syndr Date: 2012-10-01 Impact factor: 3.731
Authors: Michael A Horberg; Leo B Hurley; Michael J Silverberg; Daniel B Klein; Charles P Quesenberry; Michael J Mugavero Journal: AIDS Patient Care STDS Date: 2013-07-19 Impact factor: 5.078